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Devices that use a scintillating screen viewed via a CCD camera have 
shown to be very efficient in the collection of large amount of data 
during clinical-commissioning (e.g.  beam width in air for different 
energies in case of scanning). The electronic read-out of such devices 
can be very advantageous since it allows on-line analysis of the data 
just measured. Amorphous silicon detectors are also worth mentioning 
since they have shown promising properties and may play an 
important role in the future.   
Relative dosimetry along the beam direction has the purpose to 
measure pencil beam depth-dose curves or depth-dose profile for 
homogenous SOBP. Large plane-parallel ICs (e.g., diameter > 8cm) are 
ideal tools for integral depth dose measurements in case of scanning. 
In addition to the charged deposited by the primary beam, the wide 
active area of large plane-parallel ICs allows collecting the charged 
deposited also by secondary proton propagation under larger angles. 
Alternatively, small plane-parallel ICs in broad beams could also be 
employed to obtain pencil beam depth dose curves when the chamber 
is significantly smaller than the lateral size of the field, which is 
usually the case in passive scattering. Plane-parallel chambers are 
also ideal for measurements of the distal fall-off. Multi-layer 
ionization chambers (MLIC) can effectively measure and verify the 
range of a large number of beam energies and can be used for routine 
QA.  
Detectors for relative 3D dosimetry, which combine 1) and 2), such as, 
gel and PRESAGE, were tested under proton radiation but, as of today, 
they are still not employed routinely, mainly because of the LET and 
energy dependence and the time-consuming preparation and 
evaluation.  
 
 SYMPOSIUM: DELINEATION TOOLS FOR NORMAL 
STUCTURES  
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Contouring is the cornerstone of modern radiotherapy. Inconsistencies 
in contouring target and critical structures can seriously undermine 
the precision of conformal radiation therapy planning and are 
generally considered to be the biggest and most unpredictable source 
of systematic errors in radiation oncology. The importance of 
« correct contours » for organs at risk is crucial to asses and to predict 
early and late toxicities. The relevance of dose constraints to organs 
at risk when establishing and validating a dosimetry highly relies on 
the contouring of organs at risk. In addition normal tissue contours 
may help in patient positioning or for the assessment of dose through 
adaptive schemes in particular with image guided radiation therapy. 
Several studies have shown strong interobserver variability in organs 
at risk contouring and its dosimetric consequences indicating the need 
for a system to reduce this variability. Several methods have been 
used to improve contouring accuracy. An increasing number of 
guidelines on the contouring of organs at risk have been published 
over the last years. Contouring atlases have demonstrated to serve as 
a robust tool for accurate delineation of organs at risk. Despite 
anatomical definition for organs at risk some discrepancies remain 
even when using guidelines possibly due to miss-interpretation of the 
guidelines, of anatomical images or use of suboptimal imaging 
modality. 
In this context ESTRO decided to create a multifunctional platform for 
contouring to offer online educational and professional services. 
FALCON is a web-based service that provides hands on training tool 
available from any computer connected to the internet. FALCON was 
created in 2010 and has already achieved a number of various 
activities as it was successfully used in 19 different ESTRO courses and 
pre-meeting courses, 12 live and online contouring workshops, 2 on 
line free cases open to all ESTRO members at any time most 
convenient for them. FALCON has been used for the development and 
dissemination of contouring guidelines. Repeated evaluation of the 
use of FALCON have been performed and analyzed. 
Due to its success an exponential developing plan is made for FALCON 
in the coming years with implementation of new live and on-line 
ESTRO workshops, multiplication of the free on-line ESTRO cases, 
integration of this service in more ESTRO teaching courses, possible 
access to a library of ESTRO cases and methodological and pedagogical 
developments that will need further evaluation. In the future FALCON 
could be putted into a broader perspective serving clinical and 
pedagogical research programs, as a quality assurance tool. 
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Background: The tremendous technological development that involves 
the field of Radiotherapy is modifying all the phases of treatments, 
with a great impact in the Treatment Planning step.  
Since the era of modulated radiotherapy allowed us to prescribed 
dose to the organ at risk (OaR) as well as to the target volume, 
delineation is becoming complex and, overall, time consuming. 
Moreover, practice of replanning, increased the flow of imaging that 
must be contoured (replanning CT, CBCT images). 
In the last few years we have seen the development and the 
implementation of the Atlas-based autosegmentation softwares tested 
for clinical practice use, which could have an impact in the daily 
workflow of treatment planning.   
These systems simply called “autocontouring softwares” base their 
function on the possibility to contour various structures automatically 
with ensuring the consistency of delineation and time saving. 
Purpose: The object of the presentation is to evaluate the reliability, 
the time efficiency and to show the basic tools for the evaluation of 
the structure delineation of an ideal workflow using an autocontouring 
system. Smart Segmentation Knowledge Based Contouring® (SS-KBC), 
developed by Varian, has been used in a research program in pelvic 
delineation of locally advanced rectal cancer.  
Methods: 14 consecutive patients were selected between October-
December 2011. The images of 4 were used as an atlas and  10 used 
for validation.  Two independent  operators participated – a 
Delineator to contour and a Reviewer to perform an independent 
check (IC). The CTV, pelvic subsites and OAR were contoured. RT 
were involved in the the OaR delineation. Contouring session have 
been divided in four different sequences These included A: manual, 
B: autosegmentation,  C: autosegmentation +manual revision, and 
D: manual +auto-segmentation+manualrevision. Contouring was 
performed by the Delineator using the same planning CT.  All of them 
underwent an independent check by a Reviewer. The time required 
for all the contours were recorded and overlapping evaluation was 
assessed using Dice coefficient. 
Results: In the clinical practice setting there have been 13 min of 
time sparing between sequences A vs. sequences B (from 38 min to 25 
min, p=0.002), a mean Dice coefficient in favor of sequences A for 
CTV and all subsites (p=0.0195). In the educational/training setting 
there have been 35.2min time sparing between sequence C and D 8 
from 73.1min to 37.9 min, p=0.002). 
Conclusion: The preliminary data suggest that  the use of SS-KBC may 
help to improve time sparing  in contouring  in the clinical practice 
setting, without avoiding Indipendent Check, and it could have a 
tutorial role in the educational/training setting. Two prospective 
studies are ongoing in a larger series of patients. 
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Purpose: In 2009 an initial version of atlas-based autosegmentation 
(ABAS, Elekta) was provided to our department for validation and 
clinical evaluation. In this presentation the main results will be 
presented and the current application of this software in our daily 
clinical practice will be presented. 
Methods and Materials: Basic input for the auto-contouring software 
are one or more so called atlases. Atlases consist of fully contoured 
reference CTs for a specific treatment site. Using either a single atlas 
or multiple atlases a structure set for a new CT can be automatically 
generated. In an initial study we evaluated the differences between 
the use of a single-subject atlas versus a multi-subject atlas for head 
and neck cancer patients. Next, a clinical validation study on the 
application of auto-contouring software for this target site was 
performed1. To assess the quality of the automatically generated 
contours, the similarity between those structures, edited auto-
contours and manually delineated contours by an expert were derived 
using dice coefficients and mean distance between structure sets. In 
addition the impact of using the auto-contouring software on hands-on 
time was assessed. In a final study, the necessity of editing 
automatically generated contours before using them for treatment 
planning was evaluated2. Clinically acceptable IMRT plans were 
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generated based on the not-edited auto-contours. These plans were 
than evaluated on the edited auto-contours by two different 
observers.   
Results: Atlases used for auto-segmentation should carefully be 
selected, and validated in great detail to reach the most accurate 
segmentations. Compared to the use of a single-subject atlas, 
application of a multi-subject atlas improved the accuracy of the 
auto-contours. In the clinical validation study, an expert panel scored 
all auto-contours as ‘minor deviation, editable’ or better.  Compared 
to manual contouring, editing auto-contours reduced the hands-on 
time from 180 to 66 minutes. The dosimetric study showed that 
editing of auto-contoured neck CTV was inevitable to avoid (large) 
underdosages in the target, even when differences between the auto-
contoured and edited structures were small. For salivary glands, the 
necessity of editing the auto-contours was less pronounced.  
Currently we are using ABAS for auto-segmentation for most 
treatment sites (head-and-neck, neurology, lung, prostate, breast). 
ABAS is also used for adaptive treatments, when a patient needs a 
new CT due to anatomical changes. By using the initially segmented 
CT set as atlas, a high-quality structure set can automatically be 
generated for the new CT in very short time, hardly needing any 
manual editing of the contours. To realize a high throughput of ABAS, 
and to minimize human errors in its use, we developed an interface to 
run ABAS in a semi-automated way. 
Conclusions: Multi-atlas based auto-contouring of CTV images proved 
to be a very useful tool for rapid delineation of target volumes and 
normal tissues. Although editing of auto-contours is inevitable, 
especially for the target, a substantial time reduction is achieved 
when editing auto-contours, instead of manually contouring from 
scratch.  
  
1. Teguh et al Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 950 
2. Voet et al Radiother. Oncol. 2011;98: 373 
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If the radiation-induced fibrotic (RIF) process involves irradiated 
tissues and organs, it is only highly symptomatic in some sparse 
delayed and irreversible local sequelae. Severity often depends on 
treatment-related factors, as radiotherapy dose-volume, combined 
chemotherapy, or combined major surgery (hematoma-lymphedema-
infection), and/or patient’s co-morbidities. There is a 
histopathological heterogeneous patchwork comprising concomitant 
active cellular areas and sclerotic matricial areas, describing a 
defective healing with overwhelmed defenses mechanisms [1]. 
Therapeutic clinical experience is dependent on the severity of 
radiation-induced fibrosis at baseline, the quality of clinical 
assessment (best scoring), the availability of effective drugs, and 
sufficient treatment duration (minimum 6 months) for a chronic 
disease (quality of trial design). Management of radiation-induced 
sequelae should include: reduction of co-morbidity factors, plus 
control of any acute inflammation (infection, traumatism..) that 
worsens the underlying injury, plus use of antifibrotic agents [2], and 
promotion of tissue regeneration.  
For moderate cases, medical management is based on an initial anti-
inflammatory treatment with steroids ± antibiotics (repeated for any 
acute phase) that promotes further drug penetration in the irradiated 
volume, followed by a pentoxifylline-tocopherol combination [3,4] (or 
statins) to reduce fibroproliferative “heart” sequelae, boosted by an 
organ-targeted drugs (antiseptic for enteritis, physiotherapy and 
gabapentin for neuromuscular disease,…) to control specific symptoms 
(microbial proliferation, neuromuscular irritation...).  
For severe injury including fibrosis and necrosis, management is again 
based on a first anti-inflammatory treatment; followed by vascular 
therapy (pentoxifylline, HBO, heparin, ACE inhibitors); or antifibrotic 
treatments especially PENTOCLO (combined pentoxifylline-tocopherol-
clodronate) best described in osteoradionecrosis [5]; or anticytokines 
(TGFb or TNF); and regenerative option (dead tissue removal, stem 
cell mobilization, graft). 
Controlled trials are necessary to identify useful drugs and their 
optimal combination (best strategy). However, to help patients with 
severe injuriy (pain, handicap, compression), we should always reduce 
radiation-induced fibrosis and also seek to compensate for tissue 
depletion by graft or cell regeneration, while taking into account 
organ specificities. 
  
[1] Delanian, Radiother Oncol 2004;73: 119-31;  
[2] Delanian,. Semin Radiat Oncol 2007; 1:99-107;  
[3] Delanian  J Clin Oncol 2005,23:8570-9;  
[4] Hamama, Radiother Oncol 2012, in press,.  
[5] Delanian, Int J Radiat Biol Phys 2011;80: 832-9. 
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Idiopathic pulmonary fibrosis (IPF) is the most frequent idiopathic 
interstitial lung disease. IPF is a rare and severe disease. Estimated 
annual incidence is 5/100 000 and median survival is 3 years. Diagnosis 
depends on clinical data (absence of a cause) a possible or typical 
Usual Interstitial Pneumonia (UIP) pattern on chest High Resolution 
CTscan, and a UIP pattern on lung biopsy, if performed (Raghu, Am J 
Respir Crit Care Med 2011; 183:788-824). In Europe a combination of 
prednisone, azathioprine and N-acetyl cysteine was the standard of 
care in IPF patients requiring a treatment, on the basis of the IFIGENIA 
study (Demedts, New Engl JMed 2005;353:2229-42). The IFIGENIA 
study compared the triple therapy with the combination of 
prednisone, azathioprine and placebo, and showed that the triple 
therapy reduced lung function decline. However, this triple therapy 
was recently shown to be harmful as compared to placebo (IPF clinical 
research network, NewEngl J Med 2012;366:1968-77).   
Currently pirfenidone is the only drug approved for the treatment of 
IPF. This drug is available in Japan since 2008, and in some European 
countries since 2011. The approval of pirfenidone by the European 
Medicines Agency was based upon three phase III trials, one in Japan 
(Taniguchi, Eur Respir J 2010;35:821-9), and two in European-North 
American countries (the CAPACITY trials) (Noble, Lancet 2011; 
377:1760-9).  Both studies showed that pirfenidone reduced the 
decline of lung function as evaluated by forced vital capacity. In the 
CAPACITY trials, there was also a reduction in the decline of the 6 
minutes walking distance, and a trend for an improved survival in the 
treated group. Tolerance of pirfenidone is acceptable with 
gastrointestinal (nausea, dyspepsia) and skin (photosensitivity, rash) 
side effects. The mode of action of pirfenidone is unknown. However 
pirfenidone has consistently demonstrated anti fibroticaction in 
different experimental models of lung (e.g. bleomycin-induced lung 
injury), heart, vessels and kidney fibrosis.  
Many other molecules are being evaluated in therapeutic trials in IPF. 
Nintedanib (also known as BIBF 1120) is currently being evaluated in 
two phase III trials, after a successful phase II study (Richeldi, New 
Engl J Med 2011; 365:1079-87). In that study, treatment with 
nintedanib (150mg twice daily) reduced lung function decline and 
decreased the incidence of acute exacerbation of IPF. Gastrointestinal 
side-effects requiring the cessation of the drug were observed in 
about 16% of the patients.  Nintedanib is a tyrosine kinase inhibitor 
targeting VEGFR, PDGFR, FGFR, and other kinases.  
Many more molecules are being evaluated in phase I and phase II 
studies (see www.clinicaltrials.gov). Most of these molecules are 
targeting one specific pathway among many pathways which have 
been shown to be activated in IPF and in experimental models 
ofpulmonary fibrosis. In the past, many molecules have failed (e.g. 
endothelin receptor antagonists, PDGFR antagonist, anti-TNF, 
warfarin, …). We hope that the new molecules being tested will 
finally allow for the improvement of IPF survival in the next future.  
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The transforming growth factor beta (TGF-β) signalling pathway plays 
a central role in the development of normal tissue fibrosis after 
irradiation. TGF-β is a key regulator of cell growth and 
differentiation; it affects the immune system and controls the 
homeostasis of extracellular matrix. Accordingly, mice lacking the 
TGF-β signalling intermediate Smad3 are protected from irradiation-
induced skin, liver and lung fibrosis. Moreover, knockdown of the TGF-
β/Smad3 downstream target Pai-1 protects mice from fibrosis after 
intestinal irradiation. Although radiation fibrosis has been extensively 
